Post-approval drug safety surveillance

Annual Review of Public Health

Volumn 31, Issue , 2010, Pages 419-437

  Gibbons, Robert D ^a   Amatya, Anup K ^a   Brown, C Hendricks ^b   Hur, Kwan ^a,c   Marcus, Sue M ^d   Bhaumik, Dulal K ^a   Mann, J John ^e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c HINES VA HOSPITAL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Adverse events; Meta analysis; Mixed effects models; Poisson regression; Propensity scores; Suicide

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADVERSE OUTCOME; BAYES THEOREM; CASE CONTROL STUDY; COHORT ANALYSIS; DEPRESSION; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; LOGISTIC REGRESSION ANALYSIS; MANTEL HAENSZEL TEST; POISSON DISTRIBUTION; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHOTHERAPY; REVIEW; SCORING SYSTEM; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; WORLD HEALTH ORGANIZATION;

ANTIDEPRESSIVE AGENTS; DRUG APPROVAL; DRUG TOXICITY; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; POISSON DISTRIBUTION; POPULATION SURVEILLANCE; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUICIDE, ATTEMPTED;

EID: 77952681350     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.012809.103649     Document Type: Review

References (63)

1. Almenoff JS. 2007. Innovations for the future of pharmacovigilance. Drug Saf. 30:631-633
2. Bate A. 2007. Bayesian confidence propagation neural network. Drug Saf. 30:623-625
3. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, et al. 1998. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54:315-321
4. Breslow NE, Day NE. 1980. Statistical Methods in Cancer Research. Vol. 1: The Analysis of Case-Control Studies. Lyon, France: IARC Sci.
5. Brewer T, Colditz GA. 1999. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 281:824-829
6. Bridge JA, Greenhouse JB, Weldon AH, Campo JV, Kelleher KJ. 2009. Suicide trends among youths aged 10 to 19 years in the United States, 1996-2005. JAMA 300:1025-1026
7. Brown CH, Wang W, Sandler I. 2008. Examining how context changes intervention impact: the use of effect sizes in multilevel mixture meta-analysis. Child Dev. Perspect. 2:198-205
8. Brown CH, Wyman PA, Brinales JM, Gibbons RD. 2007. The role of randomized trials in testing interventions for the prevention of youth suicide. Int. Rev. Psychiatr. 19(6):617-631
9. Cochran WG. 1968. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 24:295-313
10. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control. Clin. Trials 7:177-188
11. DuMouchel W. 1999. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am. Stat. 53:177-190
12. DuMouchel W, Pregibon D. 2001. Empirical Bayes screening for multi-item association. Int. Conf. Knowl. Discov. Data Min.: Proc. ACM SIGKDD, 7th, San Francisco, pp. 67-76. San Diego, CA: ACM
13. Efron B. 1988. Logistic regression, survival analysis, and the Kaplan Meier curve. JASA 83:414-425
14. Egberts TCG. 2007. Signal detection: historic background. Drug Saf. 30:607-609
15. Evans SJW, Waller PC, Davis S. 2001. Use of proportional reporting ratios (PRR) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10:483-486
16. Gibbons RD, Brown CH, Hur K, Marcus S, Bhaumik DK, et al. 2007. Early evidence on the effects of the FDA black box warning on SSRI prescriptions and suicide in children and adolescents. Am. J. Psychiatry 164:1356-1363
17. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. 2007. The relationship between antidepressants and suicide: results of analysis of the Veterans Health Administration datasets. Am. J. Psychiatry 164:1044-1049
18. Gibbons RD, Duan N, Meltzer D, Pope A, Penhoet ED, et al. 2003. Waiting for Organ Transplantation: results of an analysis by an Institute of Medicine Committee. Biostatistics 4:207-222
19. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. 2005. The relationship between antidepressant medication use and rate of suicide. Arch. Gen. Psychiatry 62:165-172
20. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. 2006. The relationship between antidepressant prescription rates and rates of early adolescent suicide. Am. J. Psychiatry 163:1898-1904
21. Gibbons RD, Segawa E, Karabatsos G, Amatya AK, Bhaumik DK, et al. 2008. Mixed-effects Pois-son regression analysis of adverse event reports: the relationship between antidepressants and suicide. Stat. Med. 27:1814-1833
22. Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE, Bell CC, et al. 2002. Reducing Suicide: A National Imperative. Washington, DC: Natl. Acad. Press
23. Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. 2003. Association between antide-pressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ 326:1008-1012
24. Hamad TA, Laughren T, Racoosin J. 2006. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 63:332-339
25. Hand D. 2007. Principle of data mining. Drug Saf. 30:621-622
26. Hardy RJ, Thompson SG. 1998. Detecting and describing heterogeneity in meta-analysis. Stat. Med. 17:841-856
27. HaubenM, ReichL. 2004
28. Hauben M, Reich L, DeMicco J, Kim K. 2007. 'Extreme duplication' in the US FDA adverse events reporting system database. Drug Saf. 30:551-554
29. Hauben M, Zhou X. 2003. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 26:159-186
30. Hedeker D, Gibbons RD. 2006. Longitudinal Data Analysis. New York: Wiley
31. Huber PJ. 1967. The behavior of maximum likelihood estimates under nonstandard conditions. Proc. Berkeley Symp. Math. Stat. Probab., 5th, Berkeley, 1:221-233 Berkeley: Univ. Calif. Press
32. Isacsson G. 2000. Suicide prevention\a medical breakthrough? Acta Psychiatr. Scand. 102:113-117
33. Isacsson G, Bergman U, Rich CL. 1996. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J. Affect. Disord. 41:1-8
34. Ludwig J, MarcotteD. 2005. Anti-depressants, suicide and drug regulation. J. Policy Anal. Manage. 24:249-272
35. Malzahn U, Bohning D, Holling H. 2000. Nonparametric estimation of heterogeneity variance for the standardized difference used in meta-analysis. Biometrika 87:619-632
36. Markowitz JC. 2001. Antidepressants and suicide risk. Br. J. Psychiatry 178:477
37. Mittlboeck M, Heinzl H. 2006. A simulation study comparing properties of heterogeneity measures in meta-analyses. Stat. Med. 25:4321-4333
38. Ohberg A, Vuori E, Klaukka T, Lonnqvist J. 1994. Antidepressants and suicide mortality. J. Affect. Disord. 50:225-233
39. Olfson M, Shaffer D, Marcus SC, Greenberg T. 2003. Relationship between antidepressant medication treatment and suicide in adolescents. Arch. Gen. Psychiatry 60:978-982
40. Puijenbroek EP, Bate A, Leufkens H, Lindquist M, Orre R, Egberts A. 2002. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11:3-10
41. Rawlins M. 1984. Postmarketing surveillance of adverse reactions to drugs. Br. Med. J. 228:879-880
42. Rich CL. 1999. Relationship between antidepressant treatment and suicide. J. Clin. Psychiatry 60:340
43. Rihmer Z, Rutz W, Pihlgren H, Pestality P. 1998. Decreasing tendency of seasonality in suicide may indicate lowering rate of depressive suicides in the population. Psychiatry Res. 81:233-240
44. Rosenbaum P, Rubin DB. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-50
45. Rosenbaum PR. 1994. Coherence in observational studies. Biometrics 50:368-374
46. Rosenbaum PR. 1997. Signed rank statistics for coherent predictions. Biometrics 53:556-566
47. Rosenbaum PR. 2004. Design sensitivity in observational studies. Biometrika 91:153-164
48. Rosenbaum PR. 2006. Differential effects and generic biasesinobservational studies. Biometrika93:573-586
49. Shalviri G, Mohammad K, Majdzadeh R, Gholami K. 2007. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. Pharmacoepidemiol. Drug Saf. 16:1136-1140
50. Sidik K, Jonkman JN. 2005. Simple heterogeneity variance estimation for meta-analysis. Appl. Stat. (J. R. Stat. Soc. C). 54:367-384
51. Sidik K, Jonkman JN. 2007. A comparison of heterogeneity variance estimators in combining results of studies. Stat. Med. 26:1964-1981
52. Simon GE, Savarino J. 2007. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am. J. Psychiatry 164:1029-1034
53. Sonesson C, Bock D. 2003. A review and discussion of prospective statistical surveillance in public health. J. R. Stat. Soc. A 166:5-21
54. Stettler C, Wandel S, Allemann S. 2007. Outcomes associated with drug-eluting and bare metal stents: a collaborative network meta-analysis. Lancet 370:937-948
55. Szarfman A, Machado SG, O'Neill RT. 2002. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25:381-392
56. Tondo L, Hennen J, Baldessarini RJ. 2001. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr. Scand. 104:163-172
57. U. S. Food Drug Adm. 2004. Clinical review: relationship between antidepressant drugs and suicidality in children. http://www. fda. gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review. pdf
58. U. S. Food Drug Adm. 2006. Clinical review: relationship between antidepressant drugs and suicidality in adults.
59. http://www. fda. gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA. pdf
60. Venning GR. 1983. Identification of adverse reaction to new drugs: Allering process and early warning systems. Br. Med. J. 286:458-460
61. White H. 1980. A heteroskedasticity-consistent covariance matrix estimator and a direct test for het-eroskedasticity. Econometrica 48:817-830
62. White H. 1982. Maximum likelihood estimation of misspecified models. Econometrica 50:1-25
63. Yang X, Freeman J, Bwire R. 2008. Data mining in pharmacovigilance practice: Which algorithm to use? Drug Saf. 31:885-960